Clinical Trial Update: Ranibizumab for Neurofibromas Associated With Neurofibromatosis 1 [EARLY_Phase 1]

View source ↗

Summary

An early-phase Phase 1 trial evaluating ranibizumab for neurofibromas in Neurofibromatosis Type 1 has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cutaneous Neurofibromas
• Neurofibromatosis Type

Drugs mentioned

• Lucentis (ranibizumab)

Snippet

Sponsor: Massachusetts General Hospital | Conditions: Neurofibromatosis Type 1, Cutaneous Neurofibromas | EARLY_Phase 1 | Status: COMPLETED